Condition
C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Oms906 Study Drug
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Oms906 Study Drug1
Active Sponsors
- Omeros Corporation1
- Omeros Corp.1
Top Investigators
Omeros Corporation
Related Conditions
- C3 Glomerulopathy1
- Idiopathic Immune Complexmediated Glomerulonephritis1